Research Paper Volume 15, Issue 21 pp 11891—11917

Figure 10. XCL2 showed potential therapeutic value in immunotherapy response (A) We performed the comparison between XCL2 and other published biomarkers based on response outcomes and the predictive power of overall survival; (B) Expression of XCL2 varies across patients with different responsiveness throughout immune checkpoint inhibitor therapy; (C) Expression of XCL2 varies in patients with different responsiveness in anti PD-1 treatment; (D) Expression of XCL2 varies in patients with different responsiveness in anti PD-L1 treatment; (E) The relationship between CDCA4 expression and expected medication response; (F) The expression levels of XCL2 in different datasets.